Neurological Manifestations of Fabry Disease: Literature Review

Marina Grigolashvili; Ekaterina Kim; Shynar Muratbekova; Sholpan Omarova; Amirzhan Smagulov; Guldana Bektas; Rustam Tuleuov; Saltanat Madibraimova; Artyom Pakhomov; Olga Parkhanovich; Ekaterina Pogorelova; Gulsara Kiyakpaeva

doi:10.3889/oamjms.2022.9681

Authors

Marina Grigolashvili Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Ekaterina Kim Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Shynar Muratbekova Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Sholpan Omarova Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Amirzhan Smagulov Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Guldana Bektas Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Rustam Tuleuov Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Saltanat Madibraimova Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Artyom Pakhomov Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Olga Parkhanovich Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Ekaterina Pogorelova Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India
Gulsara Kiyakpaeva Department of Neurology, Psychiatry and Rehabilitation, NCJSC “Medical University of Karaganda”, Karaganda, Kazakhstan, India

DOI:

https://doi.org/10.3889/oamjms.2022.9681

Keywords:

Anderson-fabry disease, Fabry disease, Neurological manifestations, Neuropathic pain, Stroke, Headache, Vertigo, Parkinsonism, Multiple sclerosis, Diagnosis, Treatment

Abstract

BACKGROUND: Fabry disease (FD) or Anderson FD is a hereditary disease belonging to the group of lysosomal storage diseases caused by decreased or absent activity of the enzyme α-galactosidase A. Enzyme deficiency leads to accumulation of glycospholipids in the lysosomes of cells of various organs, including the heart, kidneys, nervous system, and vascular endothelium. The complexity of the diagnosis of FD is due to the variety of its symptoms, the simultaneous involvement of many organs and systems. At present, possible pathogenetic treatment of the disease is enzyme replacement therapy, but its effectiveness is reduced in the later stages of the disease, when there are irreversible abnormal changes in vital organs and systems. In this regard, an urgent task is the early diagnosis of FD.

AIM: Determination of neurological manifestations of FD as well as clinical criteria for screening for FD.

MATERIALS AND METHODS: We analyzed cohort studies, randomized controlled trials, systematic reviews and meta-analyses, case-control studies, and case series from scientific medical databases: PubMed, Web of Science, Google Scholar in Russian, and English languages.

CONCLUSION: The authors found that lesions of the nervous system in FD are detected in more than 80% of patients and can manifest as isolated or combined lesions of both the central and peripheral and autonomic nervous systems.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Klingelhöfer D, Braun M, Seeger-Zybok RK, Quarcoo D, Brüggmann D, Groneberg DA. Global research on fabry’s disease: Demands for a rare disease. Mol Genet Genomic Med. 2020;8(9):e1163. https://doi.org/10.1002/mgg3.1163 PMid:32031327 DOI: https://doi.org/10.1002/mgg3.1163

Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with fabry disease. Ther Clin Risk Manag. 2020;16:551-8. https://doi.org/10.2147/TCRM.S247814 PMid:32606714 DOI: https://doi.org/10.2147/TCRM.S247814

Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416-27. https://doi.org/10.1016/j.ymgme.2018.02.014 PMid:29530533 DOI: https://doi.org/10.1016/j.ymgme.2018.02.014

Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: A systematic literature review. Genet Med. 2015;17(5):323-30. https://doi.org/10.1038/gim.2014.120 PMid:25232851 DOI: https://doi.org/10.1038/gim.2014.120

Calabrese E, Rodriguez Botta G, Rosenfeld DP. New mutation in fabry disease: c.448delG, first phenotypic description. Mol Genet Metab Rep. 2021;27:100708. https://doi.org/10.1016/j.ymgmr.2021.100708 PMid:33732617 DOI: https://doi.org/10.1016/j.ymgmr.2021.100708

Mignani R, Pieruzzi F, Berri F, Burlina A, Chinea B, Gallieni M, et al. Fabry stabilization index (FASTEX): An innovative tool for the assessment of clinical stabilization in fabry disease. Clin Kidney J. 2016;9(5):739-47. https://doi.org/10.1093/ckj/sfw082 PMid:27679722 DOI: https://doi.org/10.1093/ckj/sfw082

Burand AJ Jr, Stucky CL. Fabry disease pain: Patient and preclinical parallels. Pain. 2021;162(5):1305-21. https://doi.org/10.1097/j.pain.0000000000002152 PMid:33259456 DOI: https://doi.org/10.1097/j.pain.0000000000002152

Rickert V, Kramer D, Schubert AL, Sommer C, Wischmeyer E, Üçeyler N. Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male fabry patients with pain. Exp Neurol. 2020;324:113134. https://doi.org/10.1016/j.expneurol.2019.113134 PMid:31778662 DOI: https://doi.org/10.1016/j.expneurol.2019.113134

Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the fabry registry. J Inherit Metab Dis. 2007;30(2):184-92. https://doi.org/10.1007/s10545-007-0521-2 PMid:17347915 DOI: https://doi.org/10.1007/s10545-007-0521-2

Weissmann C, Albanese AA, Contreras NE, Gobetto MN, Castellanos LC, Uchitel OD. Ion channels and pain in fabry disease. Mol Pain. 2021;17:17448069211033172. https://doi.org/10.1177/17448069211033172 PMid:34284652 DOI: https://doi.org/10.1177/17448069211033172

Siedler G, Káhn AK, Weidemann F, Wanner C, Sommer C, Üçeyler N. Dyshidrosis is associated with reduced amplitudes in electrically evoked pain-related potentials in women with fabry disease. Clin Neurophysiol. 2019;130(4):528-36. https://doi.org/10.1016/j.clinph.2019.01.008 PMid:30785009 DOI: https://doi.org/10.1016/j.clinph.2019.01.008

Godel T, Bäumer P, Pham M, Köhn A, Muschol N, Kronlage M, et al. Human dorsal root ganglion in vivo morphometry and perfusion in fabry painful neuropathy. Neurology. 2017;89(12):1274-82. https://doi.org/10.1212/WNL.0000000000004396 PMid:28835396 DOI: https://doi.org/10.1212/WNL.0000000000004396

İnan R, Meşe M, Bicik Z. Multidisciplinary approach to fabry disease: From the eye of a neurologist. Acta Neurol Belg. 2020;120(6):1333-9. https://doi.org/10.1007/s13760-019-01138-y PMid:30968323 DOI: https://doi.org/10.1007/s13760-019-01138-y

Martins AM, Cabrera G, Molt F, Suárez-Obando F, Valdés RA, Varas C, et al. The clinical profiles of female patients with fabry disease in Latin America: A fabry registry analysis of natural history data from 169 patients based on enzyme replacement therapy status. JIMD Rep. 2019;49(1):107-17. https://doi.org/10.1002/jmd2.12071 PMid:31497488 DOI: https://doi.org/10.1002/jmd2.12071

Pensabene L, Sestito S, Nicoletti A, Graziano F, Strisciuglio P, Concolino D. Gastrointestinal symptoms of patients with fabry disease. Gastroenterol Res Pract. 2016;2016:9712831. https://doi.org/10.1155/2016/9712831 PMid:26880903 DOI: https://doi.org/10.1155/2016/9712831

Lenders M, Brand E. Fabry disease: The current treatment landscape. Drugs. 2021;81(6):635-45. https://doi.org/10.1007/s40265-021-01486-1 PMid:33721270 DOI: https://doi.org/10.1007/s40265-021-01486-1

Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1):129437. https://doi.org/10.1016/j.bbagen.2019.129437 PMid:31526868 DOI: https://doi.org/10.1016/j.bbagen.2019.129437

Namer B, Ørstavik K, Schmidt R, Mair N, Kleggetveit IP, Zeidler M, et al. Changes in ionic conductance signature of nociceptive neurons underlying fabry disease phenotype. Front Neurol. 2017;8:335. https://doi.org/10.3389/fneur.2017.00335 PMid:28769867 DOI: https://doi.org/10.3389/fneur.2017.00335

Albano B, Dinia L, Del Sette M, Gandolfo C, Sivori G, Finocchi C. Fabry disease in patients with migraine with aura. Neurol Sci. 2010;31(Suppl 1):S167-9. https://doi.org/10.1007/s10072-010-0314-5 PMid:20464614 DOI: https://doi.org/10.1007/s10072-010-0314-5

Rost NS, Cloonan L, Kanakis AS, Fitzpatrick KM, Azzariti DR, Clarke V, et al. Determinants of white matter hyperintensity burden in patients with fabry disease. Neurology. 2016;86(20):1880-6. https://doi.org/10.1212/WNL.0000000000002673 PMid:27164662 DOI: https://doi.org/10.1212/WNL.0000000000002673

Sawada J, Nakagawa N, Kano K, Saito T, Katayama T, Sawada T, et al. Characteristics of neurological symptoms in adult Japanese patients with fabry disease. Intern Med. 2021;60(12):1819-26. https://doi.org/10.2169/internalmedicine.6420-20 PMid:33456042 DOI: https://doi.org/10.2169/internalmedicine.6420-20

Germain DP, Benistan K, Halimi P. Chiari Type I malformation in four unrelated patients affected with fabry disease. Eur J Med Genet. 2006;49(5):419-25. https://doi.org/10.1016/j.ejmg.2006.01.007 PMid:16510324 DOI: https://doi.org/10.1016/j.ejmg.2006.01.007

Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Müntze J, et al. Characterization of vertigo and hearing loss in patients with fabry disease. Orphanet J Rare Dis. 2018;13(1):137. https://doi.org/10.1186/s13023-018-0882-7 PMid:30111353 DOI: https://doi.org/10.1186/s13023-018-0882-7

Mishra V, Banerjee A, Gandhi AB, Kaleem I, Alexander J, Hisbulla M, et al. Stroke and fabry disease: A review of literature. Cureus. 2020;12(12):e12083. https://doi.org/10.7759/cureus.12083 PMid:33489501 DOI: https://doi.org/10.7759/cureus.12083

Brooks JB, Fragoso YD. Neurological manifestations in fabry disease. Neuroimmunol Neuroinflammation 2016;3:228-31. https://doi.org/10.20517/2347-8659.2016.36 DOI: https://doi.org/10.20517/2347-8659.2016.36

Cocozza S, Russo C, Pontillo G, Pisani A, Brunetti A. Neuroimaging in fabry disease: Current knowledge and future directions. Insights Imaging. 2018;9(6):1077-88. https://doi.org/10.1007/s13244-018-0664-8 PMid:30390274 DOI: https://doi.org/10.1007/s13244-018-0664-8

Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of fabry disease in patients with cryptogenic stroke: A prospective study. Lancet. 2005;366(9499):1794-6. https://doi.org/10.1016/S0140-6736(05)67635-0 PMid:16298216 DOI: https://doi.org/10.1016/S0140-6736(05)67635-0

Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al. Acute cerebrovascular disease in the young: The stroke in young fabry patients study. Stroke. 2013;44(2):340-9. https://doi.org/10.1161/strokeaha.112.663708 PMid:23306324 DOI: https://doi.org/10.1161/STROKEAHA.112.663708

Malavera A, Cadilhac DA, Thijs V, Lim JY, Grabsch B, Breen S, et al. Screening for fabry disease in young strokes in the Australian stroke clinical registry (AuSCR). Front Neurol. 2020;11:596420. https://doi.org/10.3389/fneur.2020.596420 PMid:33324335 DOI: https://doi.org/10.3389/fneur.2020.596420

Tomek A, Petra R, Schwabová JP, Olšerová A, Škorňa M, Nevšímalová M, et al. Nationwide screening for fabry disease in unselected stroke patients. PLoS One. 2021;16(12):e0260601. https://doi.org/10.1371/journal.pone.0260601 PMid:34905550 DOI: https://doi.org/10.1371/journal.pone.0260601

Wise AH, Yang A, Naik H, Stauffer C, Zeid N, Liong C, et al. Parkinson’s disease prevalence in fabry disease: A survey study. Mol Genet Metab Rep. 2017;14:27-30. https://doi.org/10.1016/j.ymgmr.2017.10.013 PMid:29159076 DOI: https://doi.org/10.1016/j.ymgmr.2017.10.013

Gago MF, Azevedo O, Guimarães A, Vide AT, Lamas NJ, Oliveira TG, et al. Parkinson’s disease and fabry disease: Clinical, biochemical and neuroimaging analysis of three pedigrees. J Parkinsons Dis. 2020;10(1):141-52. https://doi.org/10.3233/JPD-191704 PMid:31594250 DOI: https://doi.org/10.3233/JPD-191704

Lackova A, Beetz C, Oppermann S, Bauer P, Pavelekova P, Lorincova T, et al. Prevalence of fabry disease among patients with parkinson’s disease. Parkinsons Dis. 2022;2022:1014950. https://doi.org/10.1155/2022/1014950 PMid:35111290 DOI: https://doi.org/10.1155/2022/1014950

Böttcher T, Rolfs A, Tanislav C, Bitsch A, Köhler W, Gaedeke J, et al. Fabry disease underestimated in the differential diagnosis of multiple sclerosis? PLoS One. 2013;8(8):e71894. https://doi.org/10.1371/journal.pone.0071894 PMid:24015197 DOI: https://doi.org/10.1371/journal.pone.0071894

Shribman SE, Shah AR, Werring DJ, Cockerell OC. Fabry disease mimicking multiple sclerosis: Lessons from two case reports. Mult Scler Relat Disord. 2015;4(2):170-5. https://doi.org/10.1016/j.msard.2015.01.001 PMid:25787193 DOI: https://doi.org/10.1016/j.msard.2015.01.001

Yau WY, Fabis-Pedrini MJ, Kermode AG. Fabry heterozygote mimicking multiple sclerosis. BMJ Case Rep. 2017;2017:bcr2017220274. https://doi.org/10.1136/bcr-2017-220274 PMid:28576916 DOI: https://doi.org/10.1136/bcr-2017-220274

Colomba P, Zizzo C, Alessandro R, Cammarata G, Scalia S, Giordano A, et al. Fabry disease and multiple sclerosis misdiagnosis: The role of family history and neurological signs. Oncotarget. 2018;9(8):7758-62. https://doi.org/10.18632/oncotarget.23970 PMid:29487688 DOI: https://doi.org/10.18632/oncotarget.23970

Cocozza S, Olivo G, Riccio E, Russo C, Pontillo G, Ugga L, et al. Corpus callosum involvement: A useful clue for differentiating fabry disease from multiple sclerosis. Neuroradiology. 2017;59(6):563-70. https://doi.org/10.1007/s00234-017-1829-8 PMid:28386689 DOI: https://doi.org/10.1007/s00234-017-1829-8

Ugga L, Cocozza S, Pontillo G, Russo C, Morra VB, Lanzillo R, et al. Absence of infratentorial lesions in fabry disease contributes to differential diagnosis with multiple sclerosis. Brain Behav. 2018;8(11):e01121. https://doi.org/10.1002/brb3.1121 PMid:30277321 DOI: https://doi.org/10.1002/brb3.1121

Damulin IV. Fabry’s disease: Neurological disorders. Ter Arkh. 2016;88(8):111-4. https://doi.org/10.17116/terarkh2016888111-114 PMid:28635943 DOI: https://doi.org/10.17116/terarkh2016888111-114

Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, et al. Cerebrovascular involvement in fabry disease: Current status of knowledge. Stroke. 2015;46(1):302-13. https://doi.org/10.1161/STROKEAHA.114.006283 PMid:25492902 DOI: https://doi.org/10.1161/STROKEAHA.114.006283

Cocozza S, Russo C, Pisani A, Olivo G, Riccio E, Cervo A, et al. Redefining the pulvinar sign in fabry disease. AJNR Am J Neuroradiol. 2017;38(12):2264-9. https://doi.org/10.3174/ajnr.A5420. PMid:29051208 DOI: https://doi.org/10.3174/ajnr.A5420

Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, et al. The pulvinar sign: Frequency and clinical correlations in fabry disease. J Neurol. 2008;255(5):738-44. https://doi.org/10.1007/s00415-008-0786-x PMid:18297328 DOI: https://doi.org/10.1007/s00415-008-0786-x

Manara R, Carlier RY, Righetto S, Citton V, Locatelli G, Colas F, et al. Basilar artery changes in fabry disease. AJNR Am J Neuroradiol. 2017;38(3):531-6. https://doi.org/10.3174/ajnr.A5069 PMid:28126747 DOI: https://doi.org/10.3174/ajnr.A5069

Mazanova NN, Pushkov AA, Pachomov AV, Asanov AY, Savostyanov KV. The role of globotriaosylsphingosine in the diagnosis of fabry disease in Russian patients. Med Genet. 2020;19(7):81-2. https://doi.org/10.25557/2073-7998.2020.07.81-82 DOI: https://doi.org/10.25557/2073-7998.2020.07.81-82

Balendran S, Oliva P, Sansen S, Mechtler TP, Streubel B, Cobos PN, et al. Diagnostic strategy for females suspected of fabry disease. Clin Genet. 2020;97(4):655-60. https://doi.org/10.1111/cge.13694 PMid:31860127 DOI: https://doi.org/10.1111/cge.13694

Van der Veen SJ, Hollak CE, Van Kuilenburg AB, Langeveld M. Developments in the treatment of fabry disease. J Inherit Metab Dis. 2020;43(5):908-21. https://doi.org/10.1002/jimd.12228 PMid:32083331 DOI: https://doi.org/10.1002/jimd.12228